Alpine Woods Capital Investors’s AstraZeneca AZN Stock Holding History

Alpine Woods Capital Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-149,350	Closed	-$8.46M	–	457
2016 Q4	$8.46M	Sell	149,350 -1,400	-0.9%	-$79.5K	0.47%	81
2016 Q3	$9.91M	Hold	150,750	–	–	0.55%	67
2016 Q2	$9.1M	Buy	150,750 +47,000	+45%	+$2.73M	0.54%	62
2016 Q1	$5.84M	Hold	103,750	–	–	0.34%	101
2015 Q4	$7.04M	Sell	103,750 -81,250	-44%	-$5.33M	0.38%	90
2015 Q3	$11.8M	Sell	185,000 -24,500	-12%	-$1.61M	0.64%	47
2015 Q2	$13.3M	Hold	209,500	–	–	0.68%	47
2015 Q1	$14.3M	Buy	+209,500	New	+$14.6M	0.73%	44

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Alpine Woods Capital Investors's AZN Position: Q1 2017 in Review

Alpine Woods Capital Investors sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 149,350 shares — an estimated $8.46M sold.

Alpine Woods Capital Investors first reported a position in AZN in Q1 2015 and held it in 8 quarters. The position peaked at $14.3M in Q1 2015. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Alpine Woods Capital Investors reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
Alpine Woods Capital Investors sold 149,350 AstraZeneca shares in Q1 2017, an estimated $8.46M.
Alpine Woods Capital Investors first reported a position in AstraZeneca in Q1 2015 and held it in 8 quarters.
Alpine Woods Capital Investors's AstraZeneca position peaked at $14.3M in Q1 2015.
461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2017, filed 3 May 2017.